JOURNAL ONKOLOGIE – NEWS
07. Februar 2019
ASCO-GU: Präsentation neuer Daten zu Apalutamid und Abirateronacetat
Janssen wird auf dem 2019 Genitourinary Cancers Symposium der American Society of Clinical Oncology (ASCO-GU) in San Francisco, USA, aktuelle Daten präsentieren. Diese betreffen u.a. die Therapie des nicht-metastasierten kastrationsresistenten Hochrisiko-Prostatakarzinoms (M0CRPC, nm-CRPC) mit Apalutamid und sowohl die Therapie des neu diagnostizierten metastasierten hormonsensitiven Hochrisiko-Prostatakarzinoms (mHSPC) als auch die Therapie des metastasierten kastrationsresistenten Prostatakarzinoms (mCRPC) mit Abirateronacetat.
| Anzeige: |
|
|
Poster Session A: Prostate Cancer
Thursday, 14.2.2019, 11:30 AM – 1:00 PM & 5:30 – 6:30 PM
Thursday, 14.2.2019, 1:00 – 2:35 PM
Thursday, 14.2.2019, 4:35 PM - 5:30 PM
Friday, 15.2.2019, 12:15 PM - 1:45 PM & 5:15 PM - 6:15 PM
Thursday, 14.2.2019, 11:30 AM – 1:00 PM & 5:30 – 6:30 PM
- Feng FY, et al. Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial. Abstract No. 42, Board C10
- Delanoy N, et al. Clinical progression at initiation of a life-extending therapy (LET) in metastatic Castration-Resistant Prostate Cancer (mCRPC) is associated with a poor prognosis, whatever the treatment-line: results of the CATS retrospective registry. Abstract No. 189, Board H10
Thursday, 14.2.2019, 1:00 – 2:35 PM
- Fizazi K, et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). Abstract No. 141
Thursday, 14.2.2019, 4:35 PM - 5:30 PM
- Small EJ, et al. Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC). Abstract No. 144
Friday, 15.2.2019, 12:15 PM - 1:45 PM & 5:15 PM - 6:15 PM
- Das P, et al. Abiraterone Acetate plus Prednisolone Compared with Enzalutamide in metastatic castration resistant prostate cancer before or after chemotherapy: a retrospective Study of real world data (ACES). Abstract No. 303, Board D11
Quelle: Janssen
WEITERE BEITRÄGE ZUM THEMA
DAS KÖNNTE SIE AUCH INTERESSIEREN:
